<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306185</url>
  </required_header>
  <id_info>
    <org_study_id>fibrotomia1</org_study_id>
    <nct_id>NCT04306185</nct_id>
  </id_info>
  <brief_title>Ovarian Fragmentation Study (Crespo Medical Team)</brief_title>
  <official_title>Ovarian Fragmentation Study (Crespo Medical Team)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Equipo Juana Crespo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Equipo Juana Crespo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study designed to validate Kawamura´s theory and investigation of activation of
      primordial follicles through ovarian cortex fragmentation. Our aim is to evaluate embryo
      quality following this procedure in poor ovarian responders and patients with decreased
      ovarian reserve. Secondary objectives are to assess potential association with the number of
      oocytes retrieved and pregnancy rates after IVF.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Embryo quality improvement following ovarian fragmentation (Using ASEBIR Embryo Classification, 2015)</measure>
    <time_frame>1 year</time_frame>
    <description>Embryo quality improvement following ovarian cortex fragmentation in poor ovarian responders or patients with premature ovarian insufficency using ASEBIR Classification (2015).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Follicle growth rate before and after ovarian cortex fragmentation.</measure>
    <time_frame>2 months.</time_frame>
    <description>Number of antral Follicles in IVF treatment before ovarian fragmentation and after IVF following ovarian fragmentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Oocyte number and M-II oocyte (mature oocytes) before and after ovarian cortex fragmentation.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- AntiMullerian hormone (AMH) serum levels before and two months after the procedure.</measure>
    <time_frame>2 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Number of embryos before and after ovarian cortex fragmentation.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Clinical pregnancy rate following ovarian cortex fragmentation.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ovarian Failure</condition>
  <condition>Premature Ovarian Failure</condition>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>OVARIAN FRAGMENTATION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ovarian fragmentation through laparoscopy in patients who meet criteria ( Poor ovarian responders and poor ovarian reserve).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>OVARIAN FRAGMENTATION</intervention_name>
    <description>BILATERAL OVARIAN CORTEX FRAGMENTATION USING LAPAROSCOPIC SCISSORS</description>
    <arm_group_label>OVARIAN FRAGMENTATION</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Abdominal surgery need for fertility cause.

          -  Bad embryo quality (&gt;2 cycles with &lt; 1 embryo A-B quality. With:

        A. Poor ovarian responders (previous ≤ 3 retrieved metaphase II oocytes) in a conventional
        cycle.

        B. Decreased ovarian reserve (antral follicle count (AFC) ≤ 5 or antiMullerian hormone
        (AMH) ≤ 0.5 ng/mL).

        C.Premature ovarian insufficiency according to:

          -  Patients &lt; 40 years old.

          -  At least 1 year of amenorrhea.

          -  Follitropin serum levels (FSH) &gt;35 IU/ml in two serum samples separated by at least 1
             month.

          -  Estradiol serum levels (E2) &lt; 20 pg/mL.

        Exclusion Criteria:

          1. Clinical/ultrasonographical signs of severe endometriosis ( or endometrioma).

          2. Age over 45 years (EMC)

          3. Previous ovarian/pelvic surgery. Unilateral oophorectomy.

          4. Body Mass Index &gt; 30

          5. Previous gonadotoxic treatment.

          6. Genito-urinary tract malformations.

          7. Inform consent unsigned.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ANDER MORALES VICENTE</last_name>
    <phone>628802099</phone>
    <email>andermoralesvicente@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ander Morales Vicente</name>
      <address>
        <city>Valencia</city>
        <zip>46000</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Revelli A, Marchino G, Dolfin E, Molinari E, Delle Piane L, Salvagno F, Benedetto C. Live birth after orthotopic grafting of autologous cryopreserved ovarian tissue and spontaneous conception in Italy. Fertil Steril. 2013 Jan;99(1):227-30. doi: 10.1016/j.fertnstert.2012.09.029. Epub 2012 Oct 23.</citation>
    <PMID>23102860</PMID>
  </reference>
  <reference>
    <citation>Isachenko V, Isachenko E, Keck G, Dittrich R, Montag M, van der Ven H, Mallmann P, Müller A, Distler W, Beckmann MW, Rahimi G. First live birth in germany after re-transplantation of cryopreserved ovarian tissue: original device for initiation of ice formation. Clin Lab. 2012;58(9-10):933-8.</citation>
    <PMID>23163109</PMID>
  </reference>
  <reference>
    <citation>Baird DT, Webb R, Campbell BK, Harkness LM, Gosden RG. Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at -196 C. Endocrinology. 1999 Jan;140(1):462-71.</citation>
    <PMID>9886858</PMID>
  </reference>
  <reference>
    <citation>Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, Martinez-Madrid B, Van Langendonckt A. Restoration of ovarian function after orthotopic (intraovarian and periovarian) transplantation of cryopreserved ovarian tissue in a woman treated by bone marrow transplantation for sickle cell anaemia: case report. Hum Reprod. 2006 Jan;21(1):183-8. Epub 2005 Aug 25.</citation>
    <PMID>16126712</PMID>
  </reference>
  <reference>
    <citation>Callejo J, Salvador C, González-Nuñez S, Almeida L, Rodriguez L, Marqués L, Valls A, Lailla JM. Live birth in a woman without ovaries after autograft of frozen-thawed ovarian tissue combined with growth factors. J Ovarian Res. 2013 May 7;6(1):33. doi: 10.1186/1757-2215-6-33.</citation>
    <PMID>23647552</PMID>
  </reference>
  <reference>
    <citation>Kawamura K, Kawamura N, Hsueh AJ. Activation of dormant follicles: a new treatment for premature ovarian failure? Curr Opin Obstet Gynecol. 2016 Jun;28(3):217-22. doi: 10.1097/GCO.0000000000000268. Review.</citation>
    <PMID>27022685</PMID>
  </reference>
  <results_reference>
    <citation>Donnez J, Jadoul P, Pirard C, Hutchings G, Demylle D, Squifflet J, Smitz J, Dolmans MM. Live birth after transplantation of frozen-thawed ovarian tissue after bilateral oophorectomy for benign disease. Fertil Steril. 2012 Sep;98(3):720-5. doi: 10.1016/j.fertnstert.2012.05.017. Epub 2012 Jun 13.</citation>
    <PMID>22698640</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian fragmentation</keyword>
  <keyword>Kawamura</keyword>
  <keyword>ovarian rejuvenation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

